TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact
背景
Target:
Claudin 18.2
Indication:
Gastric Cancer/Pancreatic Cancer/Biliary Tract Cancer/Other Solid Tumors
Project Status:
Phase II

TST001 is the second most advanced Claudin18.2 targeting antibody therapeutic candidate being developed globally. It is generated by using Transcenta's Immune Tolerance Breaking Technology (IMTB) platform.

 

TST001 has high affinity, and enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

 

Since August 2020, clinical trials for TST001 are ongoing in China and US (NCT04396821, NCT04495296/CTR20201281). TST001 was granted Orphan Drug Designation in the US by FDA for the treatment of patients with gastric cancer or gastroesophageal junction (GC/GEJ).

Mechanism of Action

Claudin18.2 is a transmembrane protein highly expressed in multiple solid tumor cells. In normal tissues, the expression of Claudin18.2 is restricted to the differentiated epithelial cells of the stomach. The high tissue specificity and tumor specificity makes Claudin18.2 an extremely promising target for next-generation targeted therapy.

 

TST001 kills Claudin18.2 expressing tumor cells by mechanisms of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Leveraging advanced bioprocessing technology, the fucose content of TST001 was significantly reduced during the production, which further enhanced NK cells mediated ADCC activity of TST001.

 

IP

Transcenta owns the global rights of TST001 and has filed multiple patent applications for therapeutic and diagnostic antibodies targeting Claudin18.2 .

Collabarations

1)Clinical Development Collaboration

Global clinical collaboration with BMS to evaluate TST001 in combination with Opdivo for 1L GC/GEJ cancer.





2)Academic Collaboration

Several translational studies with Peking University Cancer Hospital, Dana-Farber Cancer Institute, and Shanghai Zhongshan Hospital.

TOP